Welcome to our dedicated page for Vireo Growth news (Ticker: VREOF), a resource for investors and traders seeking the latest updates and insights on Vireo Growth stock.
Vireo Growth Inc. (VREOF) generates a steady flow of news driven by its activities in the cannabis industry, including medical and adult-use operations, multi-state expansion, and corporate transactions. As a company that describes itself as a pioneering medical cannabis operator founded in 2014, Vireo uses press releases to communicate developments in its retail footprint, cultivation and production capacity, and strategic initiatives.
Recent news items highlight several key themes. One is geographic expansion and market entry. Vireo announced an Agreement and Plan of Merger to acquire Eaze Inc., a vertically integrated cannabis retailer and delivery technology platform with operations in California, Florida, and Colorado. The company states that this transaction is intended to mark its entry into California and Florida and to strengthen its position in Colorado, with Eaze becoming a wholly owned subsidiary upon closing.
Another recurring theme is M&A and capital structure activity. Vireo has reported entering into agreements to acquire a majority of Schwazze’s senior secured convertible notes, participating in a restructuring support agreement that contemplates an asset sale to a new entity to be majority-owned by Vireo, and negotiating an Asset Purchase Agreement to acquire Colorado dispensary assets from PharmaCann Inc. These announcements detail transaction terms, consideration in subordinate voting shares, and conditions such as regulatory approvals.
Operational updates also feature prominently. Vireo issued a release announcing the launch of adult-use cannabis sales in Minnesota at its Green Goods dispensaries, noting that it dispenses both medical and adult-use products at eight locations in the state. Quarterly earnings releases provide summaries of financial performance, state-by-state revenue, and non-GAAP metrics, accompanied by management commentary on integration of acquisitions and portfolio development.
Investors and observers who follow VREOF news can use this stream of announcements to monitor transaction progress, regulatory milestones, market entries, adult-use launches, litigation resolutions, and financial reporting updates, all of which are documented through Globe Newswire releases and linked SEC filings.
Vireo Growth (CSE: VREO, OTCQX: VREOF) has completed its previously announced acquisition of all issued and outstanding shares of C21 Investments (CSE: CXXI, OTCQX: CXXIF) via a court-approved plan of arrangement under British Columbia law. C21 shareholders received 0.023052 Vireo subordinate voting shares for each C21 common share, resulting in the issuance of an aggregate 2,766,409 Vireo shares.
According to Vireo, the deal adds three Silver State Relief dispensaries and about 104,000 sq. ft. of cultivation and production, expanding its Nevada footprint to roughly 14 dispensaries and 159,000 sq. ft. of cultivation and manufacturing. C21 common shares are expected to be delisted from the CSE and OTCQX, and C21 plans to cease being a reporting issuer and deregister its shares in due course.
Vireo Growth (CSE: VREO, OTCQX: VREOF) received board authorization for a normal course issuer bid share buyback program starting August 17, 2026. The company may repurchase up to 2,426,872 subordinate voting shares on the Canadian Securities Exchange, with any repurchased shares to be cancelled.
As of August 13, 2026, Vireo Growth had 48,517,509 subordinate voting shares and 7,718 multiple voting shares outstanding, with the latter convertible into 771,800 subordinate voting shares. Purchases will be executed by Haywood Securities under an automatic repurchase plan that allows buying at prices up to US$18.75 per share, within preset parameters. The program runs until August 17, 2027 and may be amended, suspended or terminated; the company is not obligated to purchase any shares.
Vireo Growth (CSE: VREO, OTCQX: VREOF) reported Q2 2026 GAAP revenue of $209.3 million, up 335% year-over-year, with pro forma revenue of $254.9 million assuming recent acquisitions. GAAP gross profit rose to $95.3 million with a 45.5% margin, while non-GAAP adjusted EBITDA reached $41.5 million (19.8% margin).
Growth was driven by closing the Hawthorne, Eaze and Bridgewell deals and announcing acquisitions of FLUENT and C21, plus multiple post-quarter transactions including PharmaCann assets, Cannabist assets, four Ohio deals, and a merger agreement with Planet 13. Vireo ended Q2 with $122.7 million in cash, a new $65–105 million asset-based revolver, and approximately 54.4 million subordinate voting shares outstanding on a treasury-method basis.
Vireo Growth (CSE: VREO; OTCQX: VREOF; also associated with VREOD) announced that certain indirect non-cannabis subsidiaries have entered into a senior secured asset-based revolving credit facility with an initial $65 million commitment. The facility is expandable to $85 million and up to $105 million via a $20 million accordion feature, subject to customary conditions.
Borrowings bear interest at Term SOFR plus 1.75%–2.00% or base rate plus 0.75%–1.00%, depending on average availability, and include a 0.25% annual unused commitment fee. The five-year facility was arranged and led by Bank of Montreal and is secured by substantially all assets of the participating non-cannabis subsidiaries. According to Vireo, proceeds may be used to refinance existing subsidiary debt, fund working capital, capital expenditures, permitted acquisitions, and other general corporate purposes.
Vireo Growth (CSE: VREO, OTCQX: VREOF) has received all required regulatory approvals and completed its previously announced acquisition of certain Colorado retail assets from PharmaCann. Total consideration was approximately $49.0 million, paid through the issuance of Vireo subordinate voting shares and the assumption of certain liabilities, with final share consideration subject to customary closing adjustments under the Asset Purchase Agreement.
The acquired business comprises 17 dispensaries, increasing Vireo’s Colorado retail footprint to 56 operational locations. Since March 2026, Vireo had managed these PharmaCann assets under a Management Services Agreement, enabling early operational integration. With the transaction closed, the MSA concludes and the assets will be fully integrated into Vireo’s Colorado platform, where the company plans to pursue initiatives in operational excellence, margin expansion and long-term organic growth.
Vireo Growth (CSE: VREO, OTCQX: VREOF) will hold a conference call on Tuesday, August 11, 2026, at 8:00 a.m. Eastern Time to discuss its business strategy and second quarter 2026 financial results. The results will be released in a press release before the call.
Management will host the call with a question-and-answer session. Investors can join by dialing the toll-free number +1 833 461 5787 using Meeting ID 596468752, or via a live audio webcast in the Events & Presentations section of Vireo Growth’s investor relations website.
Vireo Growth (CSE: VREO, OTCQX: VREOF) entered four definitive Securities Purchase Agreements to acquire all membership interests of FarmaceuticalRx LLC, FarmaceuticalRx 2 LLC, CAOH LLC and Canoe Hill Ohio, plus certain subsidiaries. The Ohio businesses comprise eight dispensaries, a cultivation and processing facility, and related real estate, creating a vertically integrated platform in Ohio.
The aggregate purchase price is expected to be about $208 million, paid via roughly 11 million subordinate voting shares issued in three tranches over up to 180 days, with performance-based clawback on up to 25% of shares. Closing is targeted for Q4 2026, subject to regulatory approvals and customary conditions. After completing these and previously announced deals, Vireo expects to operate in 16 states with approximately 270 dispensaries. The transactions are a related party transaction under MI 61-101 due to CEO John Mazarakis’ interest in CAOH; he disclosed his conflict and recused himself, and Vireo plans to rely on valuation and minority approval exemptions.
Vireo Growth (CSE: VREO, OTCQX: VREOF) agreed to acquire all outstanding equity of Planet 13 Holdings (CSE: PLTH, OTCQX: PLNH) via a stock-for-stock merger. Each Planet 13 common share will be exchanged for 0.015383618 of a Vireo subordinate voting share, representing a 16.6% premium to Planet 13’s 20-day VWAP and a 24% premium to its July 24, 2026 close.
According to the companies, the deal is expected to add 36 dispensaries, three cultivation/production assets, and up to 2.3 million square feet of Nevada expansion capacity, strengthening Vireo’s Nevada, Florida, and Illinois presence. Pro forma, Vireo expects about 265 dispensaries across 15 states, making it the largest U.S. cannabis operator by dispensary count. Boards of both companies unanimously approved the deal, which remains subject to Planet 13 stockholder, regulatory, and listing approvals. The Merger Agreement includes a US$1.8 million termination fee payable by Planet 13 in specified circumstances, and Planet 13 shares are expected to be delisted following closing.
Vireo Growth (CSE: VREO, OTCQX: VREOF), through subsidiary Vireo Health of Arcadia, entered a definitive agreement to acquire certain cannabis cultivation, manufacturing and retail operations from subsidiaries of The Cannabist Company across Colorado, Illinois, Massachusetts, New Jersey and West Virginia for up to US$35 million.
Consideration includes up to US$18.75 million in cash at closing and up to US$16.25 million in seller notes, subject to customary adjustments and regulatory approvals. Closings are expected in stages through 2026 and into 2027. The deal could add up to 25 dispensaries, one cultivation site and one production asset, taking Vireo’s pro forma footprint to about 230 dispensaries and operations in 15 states, which Vireo said would create the second-largest U.S. dispensary network. The transaction was unanimously approved by Vireo’s board and Cannabist’s special committee and requires a Canadian Court sale approval and vesting order plus state cannabis regulatory approvals. Cannabist is conducting a court-supervised restructuring under CCAA in Canada, with related Chapter 15 proceedings recognized in the U.S.
Vireo Growth (CSE: VREO, OTCQX: VREOF) has completed its previously announced acquisition of all issued and outstanding membership interests of FarmX, LLC d/b/a PhytoNatural, jointly with Vive Penn, a joint venture between Vireo and Hive Holdings. The deal was executed under a Securities Purchase Agreement referred to as the PhytoNatural Transaction.
The acquisition includes a non-operational Pennsylvania medical cannabis retail permit that, subject to regulatory approvals, authorizes operation of up to six dispensaries in the state. Total consideration was $20.0 million, comprising $8.0 million in cash paid at closing by Vive and approximately $12.0 million to be satisfied by issuing about 645,161 Vireo subordinate voting shares at a deemed price of $18.60 per share, two years after closing, in line with the SPA terms.